Eliem Therapeutics

Yahoo Finance • 2 years ago

Eliem Therapeutics Reports Fourth Quarter and Year-End Financial Results and Business Highlights

Progressing IND-enabling studies for ETX-123 and further preclinical development of Kv7.2/3 channel opener program Implemented corporate reorganization and pipeline reprioritization extending cash runway into 2027 SEATTLE and CAMBRIDGE,... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics Provides Strategic Update and Announces Leadership Transition

Company to focus on Kv7.2/3 channel opener program and development of lead candidate, ETX-123 Pausing clinical development of ETX-155 for Major Depressive Disorder (MDD) due to challenging capital environment Implementing corporate reorg... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics at the 5th Annual Evercore ISI HealthCONx Virtual Conference

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 30, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics Reports Third Quarter Financial and Business Highlights

Positioned to initiate ETX-155 Phase 2a trial in major depressive disorder in the first quarter of 2023 with 60-milligram dose Progressing IND-enabling studies for two Kv7 pre-candidates with safety studies planned in the first quarter of... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics to Participate at Two Upcoming Investor Conferences

SEATTLE and CAMBRIDGE, United Kingdom, Nov. 08, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc., a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address unmet needs in... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics Reports Second Quarter Financial and Business Highlights

Initiated Phase 1 pharmacokinetic trial for ETX-155 with expected results in Q4 2022 Capital now expected to fund operations into 2025 SEATTLE and CAMBRIDGE, United Kingdom, Aug. 15, 2022 (GLOBE NEWSWIRE) --  Eliem Therapeutics, Inc. (... Full story

Yahoo Finance • 2 years ago

Eliem's stock slides 20% after saying it will discontinue development of pain treatment

Shares of Eliem Therapeutics Inc. tumbled 20.0% in premarket trading on Tuesday after the company said it will discontinue development of its treatment for lumbosacral radicular pain after a Phase 2a clinical trial didn't yield strong enou... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics Provides ETX-810 Program Update

SEATTLE and CAMBRIDGE, United Kingdom, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address... Full story

Yahoo Finance • 2 years ago

Eliem Announces Updated Development Plans and the Advancement of ETX-155 for the Treatment of Major Depressive Disorder

Initiating a Phase 1 pharmacokinetics trial of ETX-155 to enable a Phase 2a trial in MDD planned to commence in first quarter of 2023 Sufficient capital expected to fund operations until mid-2024 SEATTLE and CAMBRIDGE, United Kingdom, Ju... Full story

Yahoo Finance • 2 years ago

Eliem Therapeutics to Host Virtual Investor Event on July 21, 2022

SEATTLE and CAMBRIDGE, United Kingdom, July 07, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Eliem Therapeutics, Inc. – ELYM

NEW YORK, May 17, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eliem Therapeutics, Inc. (“Eliem” or the “Company”) (NASDAQ: ELYM). Such investors are advised to contact Robert S. Willoughby at... Full story

Yahoo Finance • 3 years ago

Eliem Therapeutics Reports First Quarter Financial and Business Highlights

SEATTLE and CAMBRIDGE, United Kingdom, May 16, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to address... Full story

Yahoo Finance • 3 years ago

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Eliem Therapeutics, Inc. - ELYM

NEW YORK, April 28, 2022 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Eliem Therapeutics, Inc. (“Eliem” or the “Company”) (NASDAQ: ELYM). Such investors are advised to contact Robert S. Willoughby a... Full story

Yahoo Finance • 3 years ago

Eliem Provides Update on ETX-810 and ETX-155 Clinical Programs

Phase 2a clinical trial of ETX-810 in diabetic peripheral neuropathic pain (DPNP) did not achieve the primary endpoint Phase 2a clinical trial evaluating ETX-810 in patients with lumbosacral radicular pain (LSRP) has been fully enrolled w... Full story

Yahoo Finance • 3 years ago

Eliem Therapeutics Appoints Susan Franks as Senior Vice President and Head of Regulatory Affairs

SEATTLE and CAMBRIDGE, United Kingdom, April 05, 2022 (GLOBE NEWSWIRE) -- Eliem Therapeutics, Inc. (Nasdaq: ELYM), a clinical-stage biotechnology company focused on developing novel therapies for neuronal excitability disorders to addres... Full story